Primary Objective: characterization of GPBP expression on different subsets of human leukocytesSecondary Objective: functional characterization of GPBP on these cells
ID
Source
Brief title
Condition
- Autoimmune disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Characterization of human leukocyte subsets that express GPBP.
Differences in GPBP expression in different inflammatory conditions (autoimmune
vs. healthy)
Secondary outcome
Determination of the function of GPBP on human leukocytes.
Background summary
The Goodpasture antigen-binding protein (GPBP) is a serine/threonine kinase
that binds and phosphorylates collagen type IV, which has a major role in the
organisation of the glomerular basement membrane and is the target of
autoantibodies mediating glomerulonephritis in Goodpasture syndrome. Several
studies have suggested a link between GPBP and the immune system. GPBP has been
shown to be upregulated in autoimmune conditions, to transport the signalling
lipid ceramide, to be regulated by immune signalling molecules and to interact
with pentraxins, the key activators of the complement system. However, the
exact role of GPBP in regulation of the (auto)immune response still remains
unclear. Therefore, we intend to investigate the exact role of GPBP in the
activation and modulation of the immune system.
Study objective
Primary Objective: characterization of GPBP expression on different subsets of
human leukocytes
Secondary Objective: functional characterization of GPBP on these cells
Study design
10 ml of venous blood will be obtained from patients with an autoimmune disease
or another inflammatory disease. Leukocytes will be isolated from the blood to
study GPBP expression and function on these cells. For comparison, it is
necessary to study normal, healthy blood cells as well. This will be obtained
from healthy controls.
Study burden and risks
Patients will be asked to give blood during a regular outpatient clinic visit,
so it will demand no extra time investment from the patient. For control
subject, the most important burden will be time investment. A local bruise is
possible on the site of puncture.
Universiteitssingel 50
6229 ER Maastricht
NL
Universiteitssingel 50
6229 ER Maastricht
NL
Listed location countries
Age
Inclusion criteria
Autoimmune patients: 18 - 50 years old, diagnosed with myasthenia gravis or multiple sclerose
Healthy controls: 18 - 50 years old
Exclusion criteria
no informed consent
minors or incapacitated
healthy controls: previous inflammation related disease
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
Register | ID |
---|---|
CCMO | NL33086.068.10 |
Other | nog niet gekend |
OMON | NL-OMON27227 |